97岁李嘉诚，痴迷长寿科技

Core Viewpoint - The article discusses the increasing interest of wealthy individuals, particularly Li Ka-shing, in longevity technologies as a means to extend life and combat aging, highlighting significant investments in stem cell research and anti-aging products [6][9][16]. Investment in Longevity Technologies - Li Ka-shing sold his family's stake in Shanghai and Huang Pharmaceuticals for 4.5 billion to invest in Israeli company Pluristem, which specializes in mesenchymal stem cell technology aimed at tissue repair and anti-aging [7][12]. - The investment reflects a broader trend among the wealthy to seek solutions for longevity, with Li Ka-shing's actions seen as a personal and strategic move to enhance his own lifespan [9][13]. Historical Context of Investments - Li Ka-shing has a long history of supporting health and longevity initiatives, including a $40 million donation to UC Berkeley for a biomedical center and $10 million for a genomics innovation program [10][12]. - His investment in the NAD+ anti-aging product tru niagen, which he personally endorsed after experiencing positive effects, illustrates his commitment to longevity research [12][16]. Market Potential - The article emphasizes the vast market potential for longevity technologies, driven by the wealthy's desire for extended life, as exemplified by other tech entrepreneurs pursuing extreme measures for youth [13][15]. - Li Ka-shing's investments are positioned as a strategic bet on the future of regenerative medicine and the commercialization of longevity solutions [16].